Clinical trial

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

NCT03664921

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Omnitram Oral Tablet Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Oral Tablet Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-11-15

PhasePHASE2

Conditions

Diabetic Neuropathiesunresolved

Neuropathic Painunresolved

Pain, Chronicunresolved

Interventions

Omnitram Oral TabletDRUG

Placebo Oral TabletDRUG

Sponsors & collaborators

Syntrix Biosystems, Inc.lead sponsor

DF/Net Researchcollaborator

National Institute on Drug Abuse (NIDA)collaborator

Mapped research locations

St LouisMissouri, United States1 San AntonioTexas, United States1 AnaheimCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03664921 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.